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domains including 93 items. We enhanced our previous selection of only European
HTA agencies (IQWiG, DAHTA@DIMDI, NICE, HAS, SBU) by AHRQ, MSAC, LBI, BIQG
/ GOEG, CADTH, DECIT-CGATS, HITAP. Information was collected and compared
quantitatively, choosing the item ‘cost-effectiveness threshold’ as key informa-
tion. Additionally, HTA agencies’ methodological guidelines were extracted for
PCM relevant information. Finally, information was entered into the database and
compared qualitatively. RESULTS: First five agencies differed highly in eight do-
mains (organization scope, processes, methods, dissemination, decision, imple-
mentation, and impact). They agreed in only 17-40%. Enhancement by further
agencies indicates continued heterogeneity. UK (US$32.000-48,000) and Thailand
(US$9,866) indicated explicit but generic (i.e. not specific to disease or type of tech-
nologies) thresholds; implicit use was identified in five countries (Australia, Brazil,
Canada, Sweden, USA). Germany explicitly uses disease-specific cost-effectiveness
ratios. In none of the included countries cost-effectiveness thresholds specific to
personalized medicine and/or oncology were identified, even though we found
exception rules in UK. CONCLUSIONS: Based on a systematic and comprehensive
contextual framework displaying HTA in 10 countries of four continents we iden-
tified large heterogeneity in the application of HTA. Specific guidance for innova-
tive and costly cancer interventions is lacking.
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CLINICAL TRIAL LEARNING CURVES MAY IMPACT BOTH CLINICAL AND
ECONOMIC OUTCOMES, AND INFLUENCE HEALTH TECHNOLOGY ASSESSMENT
AND REIMBURSEMENT DECISION MAKING
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OBJECTIVES:We previously presented evidence suggesting that clinical trial learn-
ing curves may affect clinical outcomes in patients in drug trials. In the current
analysis, we demonstrate the potential effect of learning curves on economic out-
comes (specifically, cost-effectiveness). METHODS: The PROWESS trial, which
evaluated drotrecogin alpha (DrotAA) for severe sepsis, was identified in our pre-
vious study and was chosen for further analysis based on several considerations: a
published analysis suggested that a clinical trial learning curve may have had a
substantial effect on outcomes in a subgroup of patients (APACHE II  25); and a
published cost-effectiveness analysis (which did not account for the learning curve
effect) was transparent and easily replicable. Furthermore, a health technology
appraisal (HTA) of DrotAA conducted in the UK cited the cost-effectiveness analy-
ses, which suggested that the incremental cost per quality-adjusted life year for
patients with APACHE II scores  25 was  US$400,000. Similarly, an Australian
reimbursement decision excluded this patient subpopulation from coverage citing
unacceptable cost-effectiveness. We replicated the cost-effectiveness analysis for
DrotAA, and used it to model the cost-effectiveness of DrotAA in the subgroup of
patients with APACHE II 25, both with and without the patients enrolled earlier in
the trial and thus potentially affected by the learning curve. RESULTS: When pa-
tients who may have been affected by the trial learning curve were excluded from
the analysis, cost-effectiveness of DrotAA improved significantly, from US$411,333
per LYG with all patients with APACHE II score 25 to US$46,395 per LYG when the
first block of patients enrolled at each site was removed from the analysis.
CONCLUSIONS: Clinical trial learning curves potentially affect both clinical and
economic outcomes, and impact reimbursement decisions. Consideration of learn-
ing curves may be important in HTAs and reimbursement decisions, particularly
when evaluating trial data in which learning curves are more likely to be present.
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OBJECTIVES: Health Technology Assessment (HTA) is relatively new concept for
Bosnia and Herzegovina health care decision-makers. Decision on reimbursement
of medicines and other technologies are made on different levels due to decen-
tralised health system and by different stakeholders (Entities/Cantonal Health In-
surance Funds-HIF, Hospitals, Ministries of Health-MoH). Objective of this survey
was skreening of current situation and understanding of HTA principles, process
and implementation in decision making proces among key stakeholders.
METHODS: A 9-question survey with INAHTA definition of HTA provided has been
distibuted to 50 stakeholders with potential influence on reimbursement decisions.
Survey include questions on current practices and process of reimbursement de-
cisions, existance of HTA body/commission, criteria for decisions and reasons for
de-listing of reimbursed technologies. Deadline for response was two months.
RESULTS: Overall response rate was 30%; 50% (6/12) of Ministries of Health, 42%
(5/12) Health Inusrance Funds and 17% (4/24) Hospitals respond. 73% respondents
use criteria for decisions on drug reimbursement, and 67% in case of other tech-
nologies. Mostly used criteria are expert opinions (47%) and pharmacoeconomic
studies provided by the manufacturer/presentative (40%), while 33% use referal
pricing as criteria. Most of respondents use mixed criteria. HTA bodies in form of
commission/expert boards are established in 7 institutinons, mostly in MoH and
HIFs. This bodies consist of physitians and pharmacists, and only two of respon-
dents include economicst into these bodies. Similar situation is observed in case od
medical devices and other technologies reimbursement decisions. De-listing is
recorded in 40% respondents but main reason was production discontinuation.
CONCLUSIONS: Although the response rate is low, it allows conclusions that cor-
relate with the experience and current practices. There is a need for a systematic
approach to HTA and adoption of clearer criteria for reimbursement decision-
making. Establishing HTA bodies consisted of trained professionals would improve
the HTA process and reimbursement decisions.
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IMPACT OF PATIENT ACCESS SCHEMES ON NICE AND SMC GUIDANCE
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OBJECTIVES: To determine whether the use of patient access schemes (PAS) in the
provision of NICE and SMC guidance could be brought into greater alignment,
leading to greater cost savings. METHODS: From a survey of technology appraisals
published on the SMC and NICE websites, the total number involving a PAS has
been assessed. Further, if a PAS is included for a particular drug in one set of
guidance, a comparison has been made of the equivalent guidance by the other
body. There are differences between NICE and SMC roles: NHS England should
fund/resource treatments recommended by NICE; NHS Scotland is expected to
consider SMC advice, but it is not binding. SMC issues guidance on all newly li-
censed medicines, unlike NICE, which prioritizes guidance where it is most needed.
RESULTS: The list of positive NICE appraisals based on the inclusion of a PAS
consists of 15 pharmaceuticals, while the same list for the SMC includes only nine.
Most products with a PAS are included in both sets of guidance, with seven of the
nine SMC PAS also included in the NICE guidance. The remaining two with SMC
PAS have not been assessed by NICE. Of eight NICE PAS not included in SMC guid-
ance, four were accepted/accepted with restricted use, e.g. lenalidomide. The NICE
PAS ensures that if a patient receives 26 treatment cycles, the manufacturer will
cover the cost of further cycles. No PAS is included in SMC guidance; therefore, NHS
Scotland has no cost cap. CONCLUSIONS: PAS are more frequently included in
manufacturers’ submissions to NICE than to SMC. SMC has approved a number of
therapies for which NICE required a PAS to improve the economic argument.
Therefore, for these drugs, NHS Scotland could potentially achieve greater cost
savings if SMC demanded similar PAS to those required by NICE.
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IN DEPTH ANALYSIS OF HEALTH TECHNOLOGY INCORPORATION IN BRAZIL. IS
THERE A COST-EFFECTIVENESS MEASURE OF THRESHOLD?
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OBJECTIVES: Recently, a study conducted in Brazil (Teich et al, 2010) evaluated the
decisions and process submitted to the Brazilian Commission on Health Technol-
ogy Incorporation (CITEC), classifying them according to therapeutic area, re-
sponse type and applicant. The study concluded that there is no clear definition of
priorities for the incorporation of a new technology; however, it did not analyze a
possible cost-effectiveness threshold for decision making. Therefore, the present
study aims to evaluate the existence of economic analysis which supports CITEC
decisions and map possible trends. METHODS: CITEC decisions and technologies
for analysis were obtained from the updated list available at the Ministry of Health
website. Only economic studies (cost-effectiveness/utility, cost-minimization and
budget impact) from the Brazilian perspective were included and the following
databases were consulted: “Medline”, “SciSearch”, “Embase”, “Biosis Preview” and
“ISPOR Outcomes Research Digest”. RESULTS: Technologies were classified in 3
categories: incorporated, not-incorporated and in-analysis; and the results from
economic evaluations were classified into: dominant /cost-saving; up to
$Brz30,000; $Brz30,000-50,000; $Brz50,000-100,000 and above $Brz100,000 per out-
come (ideally QALY or LY, but others were considered). Of the technologies that
were not-incorporated, only 2 presented economic evaluation from Brazilian per-
spective: 1 study with incremental cost up to $Brz30,000 and 1 between $Brz50-
100,000. From incorporated technologies, only 20% presented economic evalua-
tions with results belonging to all categories (including above $Brz100,000 per
outcome). From technologies in analysis, 20% had economic studies, being most of
them dominant or cost-saving.CONCLUSIONS:Apparently, there is no criterion for
health technology assessment and inclusion of new technologies in Brazilian pub-
lic system (SUS) and also a lack of quality in the economic analysis conducted.
Therefore, besides the absence of priorities, the absence of criteria for technology
incorporation could potentially lead the system to be inefficient, spending more
money than necessary and not adopting cost-saving therapies.
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SOCIETAL PREFERENCES FOR HEALTH TECHNOLOGY DISINVESTMENT POLICY:
VIEWS OF SCOTTISH TAXPAYERS – A QUALITATIVE STUDY
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University of Aberdeen, Aberdeen, UK
OBJECTIVES: Increasingly challenging economic times require challenging deci-
sions to be made regarding health technology disinvestment. Insufficient evidence
exists on societal preferences for disinvestment in publicly-funded health care
systems. This research sought to explore the acceptability of disinvestment to
Scottish taxpayers, their preferences, and whether taxpayer loss aversion is a rel-
evant factor for disinvestment policy development. METHODS: Qualitative inter-
views were conducted with a sample of Scottish taxpayers. Interviews were split
into four parts to progress thematic discussion from basic to complex, examine
consistency and identify responses potentially indicative of loss aversion. Partici-
pants were asked about their general views on the NHS and disinvestment (Part 1),
scenario-based questions on disinvestment (Part 2), to freely discuss the disinvest-
ment issues they considered important and who they thought should be involved
in making decisions (Part 3), and further scenario-based questions on health tech-
nology investment (Part 4). RESULTS: Twelve interviews were undertaken. Re-
sponses were generally consistent. Scottish taxpayers notionally accepted disin-
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vestment, recognising the NHS budget (providing free universal healthcare) was
not unlimited. Local organisation of disinvestment policy was preferred, though
some national co-ordination was felt necessary to retain equity across geographi-
cal jurisdictions. Technologies of unproven or negligible clinical benefit, or obsolete
technologies were cited as disinvestment priorities. Respondents preferred disin-
vestment decisions be clinician-led. Other decision-making groups (e.g. patients)
were expected to be biased or not sufficiently knowledgeable about the relevant
issues. When existing technologies conferred clinical benefits to (even small num-
bers of) patients, responses suggested loss aversion, even under circumstances of
increased risks alongside these benefits. Biases are uncontrolled when using a
qualitative methodology to explore these issues. CONCLUSIONS: To maximise ac-
ceptability to taxpayers, disinvestment policy-making in Scotland should prioritise
technologies of comparatively low or unproven benefit. Decisions should be local-
ly-based and clinician-led. Future research on disinvestment should utilise quan-
titative, preference-elicitation methods to minimise potential biases.
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DECISION MAKING ON BENEFIT PACKAGE OF PUBLIC HEALTH INSURANCE IN
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OBJECTIVES: With the increasing demands for health care from aging society and
rapid technological advancement, the National Health Security Office (NHSO) of
Thailand demands for the development of systematic, transparent, and participa-
tory processes for selection of new health interventions to be included into the
benefit package of universal health coverage (UC) scheme. This study reviews and
describes experiences in the development of guidelines for economic evaluation
and participatory process of key stakeholders in submission and topic selection of
new health interventions into the UC benefit package. Lessons learnt from this
initiative are drawn in order to share experiences of Thailand to other developing
countries. METHODS: Research methods comprise comprehensive literature re-
views, focus group discussion, and brainstorming meeting among key stakehold-
ers, working groups, and subcommittee members. RESULTS: Research findings
indicate that the draft guideline produced by several rounds of stakeholder con-
sultations has been gradually accepted and adjusted by policy makers and key
stakeholders. Key features of the guideline comprise a) transparency in topic se-
lection for economic appraisal with full engagement of key stakeholders; b) eco-
nomic evaluation on selected interventions using incremental cost-effectiveness
ratio (ICER); c) budget impact analysis. The ICER threshold of 1 GDP per capita for
QALY gained has been applied by the Benefit Package Subcommittee of NHSO. The
six criteria for prioritization of topics were adopted in consensus by stakeholder
consultations. In Fiscal year 2010 and 2011, this guideline was successfully applied
twice a year for topic selection, economic appraisal, and recommendations to the
sub-committee and transmitted to NHSO Board for its final decision.
CONCLUSIONS: This initiative not only produced and applied evidence informed
decisions in a transparent manner; it also strengthened and sustained institutional
capacities in generating evidence on ICER, budget impact assessment and other
ethical social considerations. The NHSO subcommittee is the platform for inter-
change between evidence and policies.
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OBJECTIVES:Healthc are reforms are inherent in any health care system across the
globe in order to take into account changes and developments worldwide on new
ways to evaluate innovative medicines. This has impacted drugs being launched in
the rare disease space. The research is aimed to understand the dynamics in pric-
ing and reimbursement environment of drugs launched in rare diseases in key
European markets. METHODS: The research involved desk research as well as
interviews with selected stakeholders in EU5, The Netherlands, Sweden, Finland
and Romania. RESULTS: In the past it was orphan drugs were able to achieve a high
price or favourable reimbursement status, largely due to International and Na-
tional OD legislation. The results inferred that factors such as the level of unmet
needs, severity of diseases, prevalence, innovation, clinical effectiveness influence
the achievable price and reimbursement. To keep up to speed to the challenges of
dynamic healthcare funding environments pharmaceutical companies have to en-
sure that the value of the product is well demonstrated with a clear value propo-
sition. When products are launched in specific markets, the HTA bodies look for
specific criteria to be fulfilled (e.g. the SMC in the UK or HAS in France).
CONCLUSIONS: Orphan drugs are facing significant challenges in the future. How-
ever, opportunities still exist for novel compounds to reach the market place and
have an impact on how rare diseases are treated. Low patient numbers, high levels
of both disease severity and unmet need and public perception can help boost the
economic argument for Orphan Drug Approval and enable strong market access.
Health Care Use & Policy Studies – Patient-Registries & Post-Marketing Studies
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USE OF A DISEASE SPECIFIC QUALITY OF LIFE TOOL IN A QUALITY ASSURANCE
SCHEME FOR DAY CASE HERNIA SURGERY
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OBJECTIVES: Outpatient services in Germany are less controlled by external qual-
ity assurance programs. Comprehensive outcome data for benchmarking or
health-care decision-making are missing e.g. for day case surgery. A quality-of-life
instrument specific to hernia repair with mesh has been recently proposed (Caro-
linas Comfort Scale, CCS). This study evaluates the integration of CCS as part of a
multicentre quality assurance scheme for outpatient surgery. METHODS: Sixteen
ambulant centres developed a web-based quality assurance scheme for hernia day
surgery in Germany. In an evaluation phase, all patients which were intended to
treat with 3-dimensional meshes, were registered with consensus into a database
through a web-based portal. CCS questionnaires were mailed to patients 4 and 12
weeks after surgery. Patients were requested to send pseudonymized responses to
an independent party for inputting answers into the database. Clinical examina-
tions were made 4 and 12 weeks postoperatively. Additional follow-up is planned
52 weeks after surgery. CSS consists of 23 questions in 7 activity- categories and 3
dimensions: sensation of mesh, movement limitations, pain. RESULTS:During the
first year (Oct 2009 to Sept 2010) 1429 patients were registered (1271 male, 158
female, median age 53 years) and treated for primary (88%) or recurrent (11%)
hernia. 1300 (90%)/1246 (87%) patients were clinically reviewed 4/12 weeks after
surgery. 1072 (75%) /1002 (70%) questionnaires were retrieved 4/12 weeks after
surgery. Patient satisfaction rate was 98%. CCS scores are shown to be decreased
from 4 to 12 weeks in all dimensions (Sensation: 0.51 to 0.35, Movement: 0.40 to
0.20, pain: 0.45 to 0.26). CONCLUSIONS: CCS, a short, hernia-specific quality-of-life
questionnaire, is easy to use and well accepted by patients. It is shown to be a
feasible instrument to evaluate patient reported outcome after day-case hernia
surgery in a web-based multicentre quality assurance system.
Health Care Use & Policy Studies – Population Health
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LEVELS OF POPULATION RISK STRATIFICATION BASED ON THE COST OF CARE
IN PATIENTS WITH CHRONIC DISEASES
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OBJECTIVES: To determine the population risk stratification based on the cost of
care (health resource use) in patients with chronic diseases in primary health care
(PC).METHODS:Multi-center observational design. We included all patients from 6
centers of PC that demanded assistance in 2010 managed by Badalona Serveis
Assistencials SA (health organization). The risk population was defined beginning
from the complexity (co-morbid chronic [CC]) and fragility (socio-demographic and
clinical criteria). Main measures: services (medical, paediatric), chronic co-morbid-
ity (CC) and direct cost model. From a group of experts identified the different
chronic conditions and population risk levels: Level 1 (no CC), level 2 (1-2 CC), level
3 (3-4 CC) and level 4 ( 5 CC). Fixed (operation) and variable costs were considered.
Statistical analysis: linear regression model (coefficient of determination [R2], de-
pendent variable: health care costs) and principal components, p0.05. RESULTS:
We included 83,090 patients, mean age 40.9 years, women: 53%. The total cost was
56.1 million / EUR. The average / unit cost: 675.3 euros. The cost for drugs was 41%.
Stratification levels: level 1 (N  36,859, 44.4%, €283.9), level 2 (N  32,644, 39.3%,
€694.8), Level 3 (N  10019, 12.1%, €1461.6, and level 4 (N  3568, 4.3%, €2331.2).
Musculoskeletal diseases (38.1%), mental (31.6%) and cardiovascular (30.4%) were
the most frequent, p 0.001. Predictive model (R2): age  23.4%, age-sex  24.1%,
age-sex-CC  41.8% (medical: 47.9%; Paediatrics: 15.1%, p 0.001). It details the
complexity and fragility of the patients for each level of stratification and clinical
services.CONCLUSIONS:The CC is associated with increased healthcare costs. The
number of co-morbidities explains much of the costs. Knowledge of the risk /
complexity / fragility of the patients should allow preventive intervention strate-
gies.
Health Care Use & Policy Studies – Prescribing Behavior & Treatment Guidelines
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COMPARISON OF THE KNOWLEDGE IN STANDARD TREATMENT GUIDELINES
AMONG MEDICAL PRACTITIONERS AND MEDICAL STUDENTS
Hettihewa LM LM, Wimalasena G, Tharanga D
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OBJECTIVES: Introduction of module in rational use of medicine (RUM) to pharma-
cology curriculum needs analysis of existing knowledge among health care work-
ers. The knowledge and attitudes of medical practitioners (MPs) and medical stu-
dents (MSs) on Standard Treatment Guidelines (STG) were assessed. METHODS:
Forty-two MPs and 120 MSs were given pretested structured questionnaire on STG
and core policies of RUM. RESULTS: Results showed that only 78 % of MPs were
confident about their knowledge in STG and 7% of them were not attentive. Knowl-
edge of MPs and MSs showed 78% and 84% on contents of STG while the knowledge
in core policies was 73% and 34% respectively. More than 99% of MSs and 71% of
MPs were attentive on the inclusion of clinical features of the illness in STG. knowl-
edge on updating and significance of STG as guidance for new prescribers of MPs
were 84% and 88% respectively while 96 % of MSs had acquainted in those two
areas. Both groups had good knowledge on STG is not an accordance with person-
nel experience (MPs-71%, MSs-74%). 80% of MSs and 75% MPs discerned that com-
mon treatment practices is not an inclusion criteria for STG. CONCLUSIONS: We
found that MSs had good knowledge about the contents of STG and skills in appli-
cation in RUM are limited. MPs were detailed on core policies & application of STG
A357V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
